DE69820633T2 - Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden - Google Patents

Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden Download PDF

Info

Publication number
DE69820633T2
DE69820633T2 DE69820633T DE69820633T DE69820633T2 DE 69820633 T2 DE69820633 T2 DE 69820633T2 DE 69820633 T DE69820633 T DE 69820633T DE 69820633 T DE69820633 T DE 69820633T DE 69820633 T2 DE69820633 T2 DE 69820633T2
Authority
DE
Germany
Prior art keywords
carbon atoms
heterocyclic group
substituted
attached
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69820633T
Other languages
German (de)
English (en)
Other versions
DE69820633D1 (de
Inventor
Daniela Salvemini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of DE69820633D1 publication Critical patent/DE69820633D1/de
Application granted granted Critical
Publication of DE69820633T2 publication Critical patent/DE69820633T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
DE69820633T 1997-06-20 1998-06-15 Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden Expired - Fee Related DE69820633T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5040297P 1997-06-20 1997-06-20
US50402P 1997-06-20
PCT/US1998/012231 WO1998058636A1 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Publications (2)

Publication Number Publication Date
DE69820633D1 DE69820633D1 (de) 2004-01-29
DE69820633T2 true DE69820633T2 (de) 2004-09-23

Family

ID=21965044

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69820633T Expired - Fee Related DE69820633T2 (de) 1997-06-20 1998-06-15 Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden

Country Status (12)

Country Link
US (2) US6180620B1 (enExample)
EP (1) EP1001752B1 (enExample)
JP (1) JP2002506445A (enExample)
AT (1) ATE256467T1 (enExample)
AU (1) AU733415B2 (enExample)
CA (1) CA2294155A1 (enExample)
DE (1) DE69820633T2 (enExample)
DK (1) DK1001752T3 (enExample)
ES (1) ES2215305T3 (enExample)
PT (1) PT1001752E (enExample)
WO (1) WO1998058636A1 (enExample)
ZA (1) ZA985376B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
ATE552260T1 (de) * 1999-01-25 2012-04-15 Nat Jewish Health Substituierte porphyrine und deren therapeutische verwendung
AU5048400A (en) 1999-05-27 2000-12-18 Monsanto Company Biomaterials modified with superoxide dismutase mimics
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20050175580A1 (en) * 2001-01-05 2005-08-11 Daniela Salvemini Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
ATE439134T1 (de) * 2001-01-19 2009-08-15 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
WO2002058686A2 (en) * 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
EP1405066B1 (en) * 2001-03-02 2015-06-17 Galera Therapeutics LLC Chromatography of metal complexes
US20040137638A1 (en) * 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
AU2002312194B8 (en) * 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
AU2002315001A1 (en) * 2001-06-08 2002-12-23 Metaphore Pharmaceuticals, Inc. Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
JP2005519852A (ja) * 2001-06-26 2005-07-07 メタファー・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の予防および／または処置のためのＳＯＤｍとコルチコステロイドの組合せ療養
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
PT1463563E (pt) * 2001-12-14 2009-03-19 Alcon Inc Miméticos de dismutase do superóxido para o tratamento de distúrbios e doenças oculares
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
EP1513537A4 (en) * 2002-06-07 2006-09-06 Univ Duke Substituted porphyrins
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
CN1717234A (zh) * 2002-12-06 2006-01-04 爱尔康公司 用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物
KR100648618B1 (ko) * 2003-11-19 2006-11-23 주식회사 웰스킨 활성 산소 억제제
KR20060101501A (ko) * 2003-12-11 2006-09-25 알콘, 인코퍼레이티드 시신경 및 망막 손상의 치료를 위한 슈퍼옥사이드디스무타제 유사체
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006069326A2 (en) * 2004-12-21 2006-06-29 Metaphore Pharmaceuticals, Inc. Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
EP2056675B1 (en) * 2006-10-12 2019-01-09 Galera Labs, LLC Methods of treating oral mucositis
WO2009065059A2 (en) 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
EP2732817B1 (en) 2008-05-23 2016-08-24 National Jewish Health A compound for use in treating injury associated with exposure to phosgene or chlorine gas
WO2013048965A1 (en) 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment
AU2017318718B2 (en) 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
CA3053779A1 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2021163397A1 (en) 2020-02-13 2021-08-19 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof
WO2025024390A2 (en) * 2023-07-21 2025-01-30 Galera Labs, Llc Carcinogenesis reduction with pentaaza macrocyclic ring complex

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4999347A (en) 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
DE69224839T2 (de) 1991-07-19 1998-10-08 Monsanto Co Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
IL125889A0 (en) 1996-03-13 1999-04-11 Monsanto Co Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
AU733415B2 (en) 2001-05-17
ATE256467T1 (de) 2004-01-15
DK1001752T3 (da) 2004-04-19
DE69820633D1 (de) 2004-01-29
CA2294155A1 (en) 1998-12-30
WO1998058636A1 (en) 1998-12-30
AU8068598A (en) 1999-01-04
EP1001752A1 (en) 2000-05-24
EP1001752B1 (en) 2003-12-17
US6395725B1 (en) 2002-05-28
ZA985376B (en) 1999-06-21
ES2215305T3 (es) 2004-10-01
PT1001752E (pt) 2004-05-31
JP2002506445A (ja) 2002-02-26
US6180620B1 (en) 2001-01-30

Similar Documents

Publication Publication Date Title
DE69820633T2 (de) Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden
DE60008374T2 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
DE3218761C2 (enExample)
EP0659410B1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
DE60118172T2 (de) Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
CH686868A5 (de) Infusionsloesung fuer die Verabreichung von Taxol.
DE69935670T2 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
DE69624699T2 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE69904922T2 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE2900203A1 (de) Krebshemmendes und krebsmetastasen verhinderndes arzneimittel
US20040219138A1 (en) Combinations of superoxide dismutase mimetics and opioids
DE69125940T2 (de) Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
DE69330638T2 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
DE60206169T2 (de) Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff
DE68907976T2 (de) Verwendung eines Thromboxan-A2-Rezeptorantagonist zur Herstellung eines Arzeneimittels zur Behandlung pulmonarer Hypertonie, die durch Protamin-induzierte Neutralisation von Heparin verursacht wird.
DE4029747C2 (de) Verwendung von Hexadecylphosphocholin zur Behandlung von Psoriasis-Erkrankungen
DE60128472T2 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloylderivaten und alkylierungsmitteln
EP2136816B1 (de) Oleylphosphocholin
DE10163421A1 (de) Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE2528460A1 (de) Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
DE2314387C3 (de) Arzneimittel zur Behandlung bösartiger Neubildungen
EP2026789A2 (de) Neue, an der tumorphysiologie orientierte formulierung eines zytostatikums, insbesondere von cis-platin
DE2117762A1 (de) Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung
DE3880579T2 (de) Pharmazeutische zusammensetzungen zur behandlung der verstopfung der luftwege.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: STROHSCHAENK UND KOLLEGEN, 85521 OTTOBRUNN

8339 Ceased/non-payment of the annual fee